The association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese

Clinica Chimica Acta

Volumn 380, Issue 1-2, 2007, Pages 191-196

  Liao, Ling Hong ^a   Zhang, Hao ^a   Lai, Man Po ^a   Lau, Kwok Wai ^b   Lai, Albert Kai Cheong ^b   Zhang, Jin Hui ^c   Wang, Qi ^c   Wei, Wei ^d   Chai, Jian Hua ^e   Lung, Maria Li ^a   Tai, Susan S W ^f   Wu, Madeline ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b TUEN MUN HOSPITAL   (Hong Kong)

^c DALIAN MEDICAL UNIVERSITY   (China)

^d PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^e FUDAN UNIVERSITY   (China)

^f Mochtar Riady Institute for Nanotechnology   (Indonesia)

Author keywords

Chinese; Colorectal carcinoma; CYP2C9; SNP

Indexed keywords

CYTOCHROME P450 2C9; GENOMIC DNA;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHINESE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA SEQUENCE; ENZYME ACTIVITY; ETHNIC GROUP; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; XENOBIOTIC METABOLISM;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CHINA; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEALTH SURVEYS; HOMOZYGOTE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING;

EID: 34047117007     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.02.033     Document Type: Article

References (32)

1. Gertig D.M., and Hunter D.J. Genes and environment in the etiology of colorectal cancer. Semin Cancer Biol 8 (1998) 285-298
2. Marchand L.L. Combined influence of genetic and dietary factors on colorectal cancer incidence in Japanese Americans. J Natl Cancer Inst Monogr 26 (1999) 101-105
3. Lafuente M.J., Casterad X., Trias M., et al. NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis 21 (2000) 1813-1819
4. Sugimura T. Nutrition and dietary carcinogens. Carcinogenesis 21 (2000) 387-395
5. Sachse C., Smith G., Wilkie M.J., et al. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23 (2002) 1839-1849
6. Goldstein J.A., and De Morais S.M. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4 (1994) 285-299
7. Shimada T., Yamazaki H., Mimura M., Inui Y., and Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270 (1994) 414-423
8. Schwarz U.I. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 33 Suppl 2 (2003) 23-30
9. Xie H.G., Prasad H.C., Kim R.B., and Stein C.M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 54 (2002) 1257-1270
10. Martinez C., Garcia-Martin E., Ladero J.M., et al. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis 22 (2001) 1323-1326
11. Chan A.T., Tranah G.J., Giovannucci E.L., Hunter D.J., and Fuchs C.S. A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma. Clin Gastroenterol Hepatol 2 (2004) 704-712
12. Bigler J., Whitton J., Lampe J.W., Fosdick L., Bostick R.M., and Potter J.D. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 61 (2001) 3566-3569
13. Landi S., Gemignani F., Moreno V., et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics 15 (2005) 535-546
14. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
15. DeLozier T.C., Lee S.C., Coulter S.J., Goh B.C., and Goldstein J.A. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther 315 (2005) 1085-1090
16. Haining R.L., Hunter A.P., Veronese M.E., Trager W.F., and Rettie A.E. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 333 (1996) 447-458
17. *2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 7 (1997) 203-210
18. Rettie A.E., and Jones J.P. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 45 (2005) 477-494
19. Wang S.L., Huang J., Lai M.D., and Tsai J.J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5 (1995) 37-42
20. Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6 (1996) 341-349
21. Gaedigk A., Casley W.L., Tyndale R.F., Sellers E.M., Jurima-Romet M., and Leeder J.S. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 79 (2001) 841-847
22. London S.J., Sullivan-Klose T., Daly A.K., and Idle J.R. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. Pharmacogenetics 7 (1997) 401-404
23. Garcia-Martin E., Martinez C., Ladero J.M., Gamito F.J., Rodriguez-Lescure A., and Agundez J.A. Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk. Cancer Lett 180 (2002) 41-46
24. Baron J.A., and Sandler R.S. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 51 (2000) 511-523
25. Takanashi K., Tainaka H., Kobayashi K., Yasumori T., Hosakawa M., and Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10 (2000) 95-104
26. McGreavey L.E., Turner F., Smith G., et al. No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenet Genomics 15 (2005) 713-721
27. Samowitz W.S., Wolff R.K., Curtin K., et al. Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Clin Gastroenterol Hepatol 4 (2006) 894-901
28. Tranah G.J., Chan A.T., Giovannucci E., Ma J., Fuchs C., and Hunter D.J. Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study. Mol Carcinog 44 (2005) 21-30
29. Yu B.N., Luo C.H., Wang D., et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta 348 (2004) 57-61
30. *3 with hyperlipidaemia in Chinese. Br J Clin Pharmacol 60 (2005) 629-631
31. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 24 (1999) 339-346
32. Bebia Z., Buch S.C., Wilson J.W., et al. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 76 (2004) 618-627